Company Mission and Focus

Organon positions itself as a company dedicated to women's health, recognizing what it describes as decades of underinvestment in the health needs of women worldwide. The company's stated purpose centers on delivering impactful medicines and solutions for a healthier every day, with a particular emphasis on addressing unmet medical needs in areas that disproportionately affect women.

Beyond its women's health focus, Organon operates across three main business areas that together form the foundation of its commercial strategy:

• Women's Health
• Biosimilars
• Established Brands

What the Company Does

Organon develops, manufactures, and commercializes a wide range of prescription pharmaceutical products distributed across more than 140 markets globally. The company operates manufacturing and supply chain facilities and partners with other pharmaceutical and biotechnology companies to license, acquire, and co-develop products. A key part of its growth strategy involves business development activities, including acquisitions and partnerships that expand its portfolio in women's health and related therapeutic areas.

The company serves patients, healthcare providers, hospitals, pharmacies, and distributors, offering treatments that span contraception, fertility, menopause, osteoporosis, cardiovascular conditions, respiratory diseases, dermatology, and non-opioid pain management, among other areas.

Products and Services

Women's Health

Women's health represents the strategic heart of Organon's identity. Its portfolio in this space includes:

• Contraceptive products such as Nexplanon/Implanon NXT (an etonogestrel contraceptive implant), which is one of the company's flagship products in the long-acting reversible contraception category.
• NuvaRing, a vaginal contraceptive ring.
• Fertility treatments, including a range of products used in assisted reproductive technology and in vitro fertilization protocols, such as Follistim/Puregon, Ganirelix, and related hormonal therapies.
• Products addressing menopause and hormone-related conditions.
• Jada System, a device designed to help control abnormal postpartum uterine bleeding and hemorrhage.

Biosimilars

Organon has built a growing biosimilars business, often in collaboration with partner companies such as Samsung Bioepis. Biosimilars are highly similar versions of already-approved biologic medicines, offering more affordable treatment options. The company's biosimilar portfolio includes products in areas such as:

• Immunology and inflammatory conditions (for example, biosimilars referencing adalimumab and infliximab).
• Oncology (including biosimilars referencing trastuzumab and bevacizumab).
• Other therapeutic categories where biosimilars provide cost-effective alternatives to originator biologics.

Established Brands

The Established Brands segment comprises a diverse collection of well-known medicines that Organon inherited from Merck. These products, while often past their peak patent-protected sales periods, continue to provide steady revenue and serve large patient populations. This portfolio spans multiple therapeutic categories, including:

• Cardiovascular medicines such as Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin), used to manage cholesterol.
• Respiratory treatments including Singulair (montelukast) and Nasonex.
• Non-opioid pain management and anesthesia products.
• Dermatology and other specialty medicines.
• Bone health treatments such as Fosamax (alendronate) for osteoporosis.

Business Development and Partnerships

A central element of Organon's operations is its active pursuit of business development opportunities. The company has completed acquisitions to bolster its women's health and specialty portfolios, including deals that added products in areas such as fertility, pregnancy-related conditions, and dermatology. Organon also enters into licensing agreements and collaborations that give it commercial rights to promising therapies developed by other organizations. This strategy allows the company to grow beyond its inherited Merck portfolio and pursue new sources of long-term revenue.

Global Presence

Organon markets its products across a wide geographic footprint that includes North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa. A significant portion of the company's revenue is generated outside the United States, reflecting the international nature of the established brands and biosimilars businesses. The company maintains manufacturing operations and a global supply chain to support the distribution of its products across these many markets.

Corporate Responsibility and Values

Organon emphasizes a commitment to expanding access to healthcare, particularly for women in underserved communities. The company frequently highlights its focus on health equity, working to reduce barriers that prevent women from receiving appropriate care. Its environmental, social, and governance efforts include initiatives related to responsible sourcing, environmental sustainability, patient access programs, and workforce diversity.

Summary

Organon & Co. is a dedicated global healthcare company that emerged from Merck in 2021 with a distinctive focus on women's health, complemented by a robust biosimilars business and a broad portfolio of established medicines. Through products spanning contraception, fertility, menopause, cardiovascular care, respiratory disease, and beyond, the company aims to address unmet medical needs and improve health outcomes for patients around the world. By combining a heritage of well-known medicines with targeted investment in women's health and biosimilars, Organon seeks to establish itself as a leading independent player in the pharmaceutical industry.